Amer J Perinatol
DOI: 10.1055/s-0037-1608634
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Comparison of Neonatal Abstinence Syndrome Treatment with Sublingual Buprenorphine versus Conventional Opioids

Eric S. Hall1, 2, Ward R. Rice1, 2, Alonzo T. Folger2, 3, Scott L. Wexelblatt1, 2
  • 1Perinatal Institute, Section of Neonatology, Perinatal and Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
  • 2Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio
  • 3Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Further Information

Publication History

03 August 2017

28 September 2017

Publication Date:
07 November 2017 (eFirst)


Objective The objective of this study was to compare duration of opioid treatment and length of stay outcomes for neonatal abstinence syndrome (NAS) using sublingual buprenorphine versus traditional weaning with methadone or morphine.

Study Design This retrospective cohort analysis evaluated infants treated for NAS at a single community hospital from July 2013 through June 2017. A standardized weaning protocol was introduced in June 2015, allowing for treatment with sublingual buprenorphine regardless of type of intrauterine opioid exposure. General linear models were used to calculate adjusted mean duration of opioid treatment and length of hospitalization with 95% confidence intervals for infants treated with buprenorphine compared with traditional weaning with either methadone or morphine.

Results A total of 360 infants were treated with either buprenorphine (n = 174) or a traditional opioid (n = 186). Infants treated with buprenorphine experienced a 3.0-day reduction in opioid treatment duration of 7.4 (6.3–8.5) versus 10.4 (9.3–11.5) days (p < 0.001) and a 2.8-day reduction in length of stay of 12.4 (11.3–13.6) versus 15.2 (14.1–16.4) days (p < 0.001).

Conclusion Our study provides an independent confirmation that among infants experiencing NAS following a wide array of intrauterine opioid exposures, buprenorphine weaning supports a shortened treatment duration compared with conventional weaning agents.